Ningbo Menovo Pharmaceutical Co., Ltd. (SHA:603538)

China flag China · Delayed Price · Currency is CNY
65.30
+5.18 (8.62%)
Apr 29, 2026, 3:00 PM CST
382.99%
Market Cap 14.40B
Revenue (ttm) 1.56B
Net Income (ttm) 112.17M
Shares Out 220.49M
EPS (ttm) 0.50
PE Ratio 130.62
Forward PE n/a
Dividend 0.05 (0.08%)
Ex-Dividend Date Jun 25, 2025
Volume 62,109,220
Average Volume 66,467,467
Open 61.26
Previous Close 60.12
Day's Range 59.85 - 65.30
52-Week Range 13.34 - 65.30
Beta -0.37
RSI 77.51
Earnings Date Apr 25, 2026

About SHA:603538

Ningbo Menovo Pharmaceutical Co., Ltd. research, develops, produces, and sells pharmaceutical products. The company’s products portfolio includes valsartan, losartan, clopidogrel, perindopril, rosuvastatin calcium, atorvastatin calcium, purin bahrain, and other products. It offers APIs, intermediates, and preparations for the treatment of cardiovascular, central nervous system, gastrointestinal tract, and other therapeutic areas. The company was founded in 2004 and is headquartered in Ningbo, China. [Read more]

Sector Healthcare
Founded 2004
Employees 2,404
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 603538
Full Company Profile

Financial Performance

In 2025, SHA:603538's revenue was 1.50 billion, an increase of 9.49% compared to the previous year's 1.37 billion. Earnings were 102.23 million, an increase of 53.02%.

Financial Statements

News

There is no news available yet.